Late last month, Boston Scientific announced it was pausing a study examining pulsed field ablation as a first-line therapy.

The technology is integrated with company’s electroanatomical mapping system, which helps guide operators during AF ablation.

Boston Scientific expects to complete enrollment in the coming months in the study comparing pulsed field ablation to ...

Johnson & Johnson MedTech will enter the U.S. pulsed field ablation market following an FDA green light for its Varipulse ...

Boston Scientific temporarily paused enrolment in its AVANT GUARD trial in October to “assess a few unanticipated ...

The VARIPULSE™ Platform is the first and only Pulsed Field Ablation (PFA) System in the U.S. fully integrated with the CARTO™ ...

Cortex adds to Boston Scientific’s electrophysiology portfolio amid treatment shifts in the space driven by new pulsed field ...

Pulse Biosciences (PLSE) announced “positive preliminary results” from its first-in-human feasibility study using Nanosecond Pulsed ...

The VARIPULSE™ Platform is the first and only Pulsed Field Ablation (PFA) System in the U.S. fully integrated with the CARTO™ 3 Electro-anatomical Mapping System, driving efficiency ...

Boston Scientific is resuming its "Avant Guard" study of pulse field ablation (PFA) as a first-line therapy for atrial ...

The AVANT GUARD trial investigates the safety and efficacy of pulsed field ablation (PFA) as a first-line treatment for persistent atrial fibrillation. Atrial fibrillation, a prevalent heart ...